B&L patent settlement
This article was originally published in The Tan Sheet
Executive Summary
Settlement agreement between Bausch & Lomb and Alcon Labs establishes a cross-licensing relationship that allows Alcon to continue selling its ICAP AREDS ocular vitamins worldwide and gives B&L global rights under one or more Alcon patents. B&L filed an infringement suit against the ICAPS manufacturer shortly after receiving a patent for its Ocuvite PreserVision line of antioxidant and mineral eye vitamins in December 2003. The formula was developed by B&L and the National Eye Institute for use in NEI's Age-Related Eye Disease Study (AREDS) and remains the only vitamin demonstrated effective in preserving eye health and vision (1"The Tan Sheet" Oct. 15, 2001, p. 3)...
You may also be interested in...
Bausch & Lomb OcuVite Line Extension Used In Natl. Eye Institute Study
Promotions for Bausch & Lomb's new Ocuvite PreserVision containing vitamins C and E, beta carotene, zinc and copper likely will stress the product's clinically proven eye health benefits.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.